Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks

por Tepper, Stewart J., Vasudeva, Raghavendra, Krege, John H., Rathmann, Suchitrita S., Doty, Erin, Vargas, Bert B., Magis, Delphine, Komori, Mika
Publicado 2020

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinica...

por Ashina, Messoud, Vasudeva, Raghavendra, Jin, Leah, Lombard, Louise, Gray, Elizabeth, Doty, Erin G., Yunes‐Medina, Laura, Kinchen, Kraig S., Tassorelli, Cristina
Publicado 2019

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

por Brandes, Jan Lewis, Klise, Suzanne, Krege, John H, Case, Michael, Khanna, Rashna, Vasudeva, Raghavendra, Raskin, Joel, Pearlman, Eric M, Kudrow, David
Publicado 2019

A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SP...

por Lipton, Richard B., Baygani, Simin K., Tepper, Stewart J., Krege, John H., Vasudeva, Raghavendra, Pearlman, Eric M., Hauck, Paula M., Loo, Li Shen
Publicado 2021